The 2009 Biotech Graveyard

Last year National Venture Capital Association President Mark Heesen predicted that the coming financial crisis would make or break many small developers. The strong would survive, and the weak would not have what it took to raise cash during the credit crunch. Today we look at that unfortunate bunch; 16 notable companies that didn't have the money, expertise or programs to live to see another day.

Though this report seems like it's all about doom and gloom, there is a silver lining here. Bankruptcies and liquidations were coming fast and furious in early 2009. Hardly a week would go by without news of yet another biotech collapse. But that's changed in the last few months as the market has stabilized and fewer companies have been forced to close.

Take a look at this list of companies that have folded since October 2008; let's hope next year's list isn't quite as long. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.